Bronchostop (Syrup) Instructions for Use
Marketing Authorization Holder
Slavic Pharmacy, LLC (Russia)
ATC Code
R05CB02 (Bromhexine)
Active Substance
Bromhexine (Rec.INN registered by WHO)
Dosage Form
| Bronchostop | Syrup 4 mg/5 ml: 100 ml bottle |
Dosage Form, Packaging, and Composition
| Syrup | 5 ml |
| Bromhexine hydrochloride | 4 mg |
100 ml – polyethylene terephthalate bottles (1) with a dosing spoon or cup – cardboard packs.
100 ml – dark glass bottles (1) with a dosing spoon or cup – cardboard packs.
Clinical-Pharmacological Group
Mucolytic and expectorant drug
Pharmacotherapeutic Group
Mucolytic agent
Pharmacological Action
Mucolytic agent with expectorant action. It reduces the viscosity of bronchial secretions by depolymerizing the acidic polysaccharides contained in it and by stimulating the secretory cells of the bronchial mucosa that produce secretions containing neutral polysaccharides.
It is believed that Bromhexine promotes the formation of surfactant.
Pharmacokinetics
Bromhexine is rapidly absorbed from the gastrointestinal tract and undergoes intensive metabolism during the first pass through the liver. Its bioavailability is about 20%. In healthy patients, the Cmax in plasma is determined after 1 hour.
It is widely distributed in body tissues. About 85-90% is excreted in the urine, mainly in the form of metabolites. The metabolite of bromhexine is ambroxol.
The binding of bromhexine to plasma proteins is high. The T1/2 in the terminal phase is about 12 hours.
Bromhexine penetrates the blood-brain barrier. It penetrates the placental barrier in small amounts.
Only small amounts are excreted in the urine with a T1/2 of 6.5 hours.
The clearance of bromhexine or its metabolites may be reduced in patients with severe hepatic and renal impairment.
Indications
Diseases of the respiratory tract accompanied by the formation of difficult-to-separate viscous secretions: tracheobronchitis, chronic bronchitis with a broncho-obstructive component, bronchial asthma, cystic fibrosis, chronic pneumonia.
ICD codes
| ICD-10 code | Indication |
| E84 | Cystic fibrosis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J44 | Other chronic obstructive pulmonary disease |
| J45 | Asthma |
| R05 | Cough |
| ICD-11 code | Indication |
| CA05 | Acute laryngitis or tracheitis |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA22.Z | Chronic obstructive pulmonary disease, unspecified |
| CA23 | Asthma |
| CA25.Z | Cystic fibrosis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| MD12 | Cough |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Orally for adults and children over 10 years old – 8 mg 3-4 times/day. For children under 2 years old – 2 mg 3 times/day; for ages from 2 to 6 years – 4 mg 3 times/day; for ages from 6 to 10 years – 6-8 mg 3 times/day.
If necessary, the dose can be increased for adults to 16 mg 4 times/day, for children – to 16 mg 2 times/day.
In the form of inhalations for adults – 8 mg, for children over 10 years old – 4 mg, for ages 6-10 years – 2 mg. For children under 6 years old – used in doses up to 2 mg. Inhalations are performed 2 times/day.
The therapeutic effect may appear on the 4th-6th day of treatment.
Parenteral administration is recommended for treatment in severe cases, as well as in the postoperative period to prevent the accumulation of thick sputum in the bronchi. Administer 2 mg subcutaneously, intramuscularly, or intravenously 2-3 times/day slowly over 2-3 minutes.
Adverse Reactions
From the digestive system: dyspeptic phenomena, transient increase in the activity of liver transaminases in the blood serum.
From the central nervous system: headache, dizziness.
Dermatological reactions: increased sweating, skin rash.
From the respiratory system: cough, bronchospasm.
Contraindications
Hypersensitivity to bromhexine.
Use in Pregnancy and Lactation
Contraindicated in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy and during breastfeeding is possible only in cases where the intended benefit to the mother outweighs the potential risk to the fetus or infant.
Use in Hepatic Impairment
Should be used with caution in patients with impaired liver function.
Use in Renal Impairment
Should be used with caution in patients with impaired renal function.
Pediatric Use
Use with caution in children – according to indications, in age-appropriate recommended doses and dosage forms.
Special Precautions
In case of gastric ulcer, as well as with a history of gastric bleeding, Bromhexine should be used under medical supervision.
Use with caution in patients suffering from bronchial asthma.
Bromhexine should not be used simultaneously with medicines containing codeine, as this makes it difficult to cough up liquefied sputum.
It is used as part of combined herbal preparations with essential oils (including eucalyptus oil, anise oil, peppermint oil, menthol).
Drug Interactions
Bromhexine is incompatible with alkaline solutions.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer